Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 161

Sort by

Sort Order Select

Journal Articles

Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression

Lilian Varricchio, Gohar Mosoyan, Sebastian Elghaity-Beckley, Md. Babu Mia, Shivani Handa, Christian Salib, John Mascarenhas, Ronald Hoffman

Blood (2025) 146 (13): 1612–1624.

https://doi.org/10.1182/blood.2024027363

Published: 2025

Includes: Supplemental data

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Moving toward disease modification in polycythemia vera

Jan Philipp Bewersdorf, Joan How, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, John Mascarenhas, Raajit K. Rampal

Blood (2023) 142 (22): 1859–1870.

https://doi.org/10.1182/blood.2023021503

Published: 2023

Journal Articles

Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study

Mark Blaine Geyer, John Mascarenhas, Marissa Smith, Shakira Pascual, Anmol Shah, Michael R. Silvestrone, Tina Czaplinska, Kathryn Johnson, Meghan C. Thompson, Jae H. Park

Blood (2023) 142 (Supplement 1): 1510.

https://doi.org/10.1182/blood-2023-173551

Published: 2023

Journal Articles

Array CGH + SNP in ALL Enhances Detection of Complex Cytogenetic Profiles and Suggests That PRSS1 Loss May Play a Role in Leukemogenesis

Hannah Levavi, Daiva Ahire, Yosef Joseph Rene Amel Riazat-Kesh, Tianxiang Sheng, Dahniel L Sastow, Jonathan Feld, Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Vesna Najfeld, Michal Bar-Natan

Blood (2023) 142 (Supplement 1): 6062.

https://doi.org/10.1182/blood-2023-185332

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Clinical Practice Gaps in Managing Patients with Myelofibrosis: Comparison of Healthcare Professional and Expert Treatment Choices Provided to an Online Decision Support Tool

Ryan P. Topping, Prithviraj Bose, John Mascarenhas, Raajit K. Rampal, Brady L. Stein, Timothy A. Quill, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 7291.

https://doi.org/10.1182/blood-2023-174268

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Ganesh Sivakumar, Shivani Handa, Andrew Srisuwananukorn, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Yelena Ginzburg, Xiaoli Wang, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2023-178822

Published: 2023

Journal Articles

Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis

Douglas Tremblay, Grace Van Hyfte, John Mascarenhas, Jonathan Feld

Blood (2023) 142 (Supplement 1): 2431.

https://doi.org/10.1182/blood-2023-179923

Published: 2023

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data

Ruben Mesa, Vikas Gupta, John Mascarenhas, Gabriella Hobbs, Jean-Jacques Kiladjian, Giacomo Coltro, Vincenzo Bagnardi, Chiara Oriecuia, Lennart Kann, Gozde Colak, Claire N Harrison, Debarshi Dey

Blood (2023) 142 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2023-179924

Published: 2023

Journal Articles

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Daniel I. Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Lewis R. Silverman, Vesna Najfeld, Jonathan Feld

Blood (2023) 142 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2023-179585

Published: 2023

Journal Articles

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Joseph Tripodi, Ronald Hoffman, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Ian Novoselac, Vesna Najfeld

Blood (2023) 142 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2023-181092

Published: 2023

Journal Articles

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Muftuoglu, Cecile Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2023-187426

Published: 2023

Journal Articles

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Stephen T. Oh, Jamile Shammo, Vikas Gupta, Mary Frances McMullin, Prithviraj Bose, Ruben A. Mesa, Alessandro Lucchesi, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas, Francisca Ferrer Marin

Blood (2023) 142 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2023-178753

Published: 2023

Journal Articles

Thrombocytopenia Associated with Myelofibrosis Is Characterized By a Reduced Proportion of Megakaryocyte (MK) Biased Hematopoietic Stem Cells, Defects in MK Maturation and Increased Levels of Pro-Inflammatory Cytokines

Lilian Varricchio, Gohar Mosoyan, Sebastian Elghaity-beckley, John Mascarenhas, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2023-178087

Published: 2023

Journal Articles

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Hannah Goulart, Dahniel L Sastow, Nicholas Dreher, Metodi Balev, Grace Van Hyfte, Marina Kremyanskaya, Ronald Hoffman, John Mascarenhas, Douglas Tremblay

Blood (2023) 142 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2023-182450

Published: 2023

Journal Articles

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Keri Maher, Raajit K. Rampal, Prithviraj Bose, Nikolai A. Podoltsev, Claire N Harrison, Junshik Hong, Xulong Wang, Kamal Chamoun, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2023-180695

Published: 2023

Journal Articles

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Helen Ajufo, Jan Philipp Bewersdorf, Claire N Harrison, Francesca Palandri, John Mascarenhas, Jeanne Palmer, Aaron T. Gerds, Jean-Jacques Kiladjian, Sarah Buckley, Andriy Derkach, Karisse Roman-Torres, Raajit K. Rampal

Blood (2023) 142 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2023-177643

Published: 2023

Journal Articles

Phase 1/2 Study of Pacritinib in Combination with Azacitidine in Chronic Myelomonocytic Leukemia

Douglas Tremblay, Alan Shih, Jonathan Feld, Erin Moshier, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2023-174960

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Moving toward disease modification in polycythemia vera

Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study

Array CGH + SNP in ALL Enhances Detection of Complex Cytogenetic Profiles and Suggests That PRSS1 Loss May Play a Role in Leukemogenesis

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Clinical Practice Gaps in Managing Patients with Myelofibrosis: Comparison of Healthcare Professional and Expert Treatment Choices Provided to an Online Decision Support Tool

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Thrombocytopenia Associated with Myelofibrosis Is Characterized By a Reduced Proportion of Megakaryocyte (MK) Biased Hematopoietic Stem Cells, Defects in MK Maturation and Increased Levels of Pro-Inflammatory Cytokines

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Phase 1/2 Study of Pacritinib in Combination with Azacitidine in Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only